Trending Topic

Human brain left x-ray view
17 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Parkinson’s disease (PD) is a complex neurodegenerative condition that predominantly affects older people, with a rising prevalence worldwide.1,2 There are many on-going challenges and unmet needs in PD: difficulties in making an accurate diagnosis (particularly in the early stages of the disease), troubling side effects associated with the available pharmacological treatments, a lack of effective disease-modifying therapies […]

Jeffrey Guptill, AAN 2021: Vivacity-MG Study Results

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: May 10th 2021

We were delighted to meet with Jeffery Guptill (Duke University Medical Center, Durham, NC, USA) to discuss the Vivacity-MG study results (NCT03772587), investigating nipocalimab as a treatment option for Myasthenia Gravis.

The abstract entitled: ‘Vivacity-MG: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.

Questions:

  1. What are the limitations of broad based immunotherapies in the treatment of myasthenia gravis (MG)? (0:18)
  2. What is nipocalimab and what is its mechanism of action? (2:52)
  3. Could you tell us a little about the Vivacity study and its efficacy and safety findings to date? (3:21)
  4. What questions remain unanswered about the clinical utility of nipocalimab in this treatment setting and what future studies are planned? (5:32)
  5. Where do you think nipocalimab will sit in the treatment paradigm for MG? (7:02)

Disclosures: Jeffrey Guptill is a consultant in past 12 months for Immunovant, Alexion, Apellis, Momenta, Ra Pharma, Grifols, Jacobus, Becton Dickinson, Cabaletta, Regeneron, Argenx, UCB, Toleranzia and Piedmont Pharmaceuticals; receives industry grant support from UCB pharma for a fellowship training grant. Full disclosure statement available at: https://dcri.org/about-us/conflict-of-interest/. Jeffrey Guptill is also a site investigator for: Alexion, Momenta, Ra Pharma, Argenx, Takeda, and receives grant/research support from: NIH (NIAID, NINDS, NIMH), and Myasthenia Gravis Foundation of America.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch,

Filmed as a highlight of AAN Annual Virtual Meeting 2021

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup